SecBot SecBot

IOVA

IOVANCE BIOTHERAPEUTICS, INC.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001425205 Biotech & Drug Discovery
$7.55 −0.21 (−2.71%)
Nov 16 4:00 PM ET · prev $7.76
Market cap
$3.5B
Mid cap
Consensus
Buy
81% Buy or better · 16 analysts
Median target
$15.50
+105% · range $8.00–20.00
1 year
+212.0%
from $2.42 · Nov 17
30 days
−46.9%
from $14.21
52-week range
$2.14–14.86
−49% from high · low Dec 2
Avg volume 20D
15.39M
Oct 29 spike 59.23M
Short interest
65.19M
≈14.1% of shares · +10.6%
Days to cover
4.2
at average volume
Insider net
$0
no open-market trades · since Mar 9
New fund stakes
3
Q3 2026 13F · 0 exits
Reddit crowd
50°
Neutral · 1 mention this week
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 4 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 9/10

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Mar 9. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q3 2026: 40 added (3 new), 21 trimmed or exited. Largest new: Arrowstreet Capital, Limited Partnership $16.6M.

  • AnalystsBULLISH

    13 of 16 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +10.6% to 65.19M shares. 4.2 days to cover, ≈14.1% of shares.

  • TrendDOWNTREND

    33% below its 50-day average.

  • SocialQUIET

    Crowd 50° (neutral) this week from 1 mention: 0 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
3
new positions
0
exits
$16.6M
in new stakes · top 1 shown
FundMoveSharesValue
UBS Group AGADD2,551,624$37.8M
Invesco Ltd.ADD2,327,991$34.5M
BNP PARIBAS FINANCIAL MARKETSDOUBLED2,077,624$30.8M
HRT FINANCIAL LPTRIM1,777,447$26.3M
FMR LLCADD1,708,446$25.3M
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPNEW1,117,445$16.6M
MARSHALL WACE, LLPDOUBLED921,413$13.7M
AMERICAN CENTURY COMPANIES INCADD856,650$12.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

16 analysts
Buy 81% rate it Buy or better
Strong Buy3Buy10Hold3Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +105%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 6, 2026Barclays
MAINTAIN
MAINTAINOverweight
Nov 6, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Nov 3, 2026UBS
MAINTAIN
MAINTAINNeutral
Oct 13, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 8, 2026Baird
MAINTAIN
MAINTAINNeutral
Sep 30, 2026Wells Fargo
MAINTAIN
MAINTAINOverweight

Insider ledger

Form 4
$0
open-market buys or sells · since Mar 9
DateInsiderTypeValue
Nov 11, 2026
Vogt Frederick G
Interim CEO & General Counsel
Nov 11, 2026
EXERCISE$1.5M
Nov 11, 2026
Vogt Frederick G
Interim CEO & General Counsel
Nov 11, 2026
TAX W/H$1.5M
Nov 10, 2026
Kirby Daniel Gordon
Chief Commercial Officer
Nov 10, 2026
EXERCISE10,000 sh
Nov 10, 2026
Kirby Daniel Gordon
Chief Commercial Officer
Nov 10, 2026
TAX W/H$31.8K
Nov 6, 2026
Roche Corleen M.
Chief Financial Officer
Nov 6, 2026
TAX W/H$42.7K
Nov 6, 2026
Roche Corleen M.
Chief Financial Officer
Nov 6, 2026
EXERCISE12,500 sh
Sep 30, 2026
Berkowitz Noah
Chief Medical Officer
Sep 30, 2026
AWARD135,000 sh
Sep 30, 2026
Berkowitz Noah
Chief Medical Officer
Sep 30, 2026
AWARD180,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q-$0.04-$0.08–-$0.02+49.7%$133.9M
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
5 drugs tracked · Drug pipeline →
Recent
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or…
Nov 5, 2026
Earnings result
IOVA Q3 2026 Earnings: EPS $-0.05 (+42.6% vs est)
Oct 28, 2026
FDA
Iovance Biotherapeutics to Host Webcast on Positive Data for TIL Therapy in Metastatic Non-Small Cell Lung Cancer (mNSCLC) and Broader Precision Medicine Strategy
Live Webcast at 8:30 a.m. ET on Thursday, October 29, 2026
Oct 27, 2026
Earnings
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…
Oct 19, 2026
Press release
Iovance Highlights TIL Cell Therapy Platform Across Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2026
Iovance Advances TIL Cell Therapy into a New Chapter in Solid Tumor Treatment Two Oral Presentations to Showcase Deep, Durable Responses with TIL…

Short side

FINRA· Oct 30, 2026
65,189,660
shares short
+10.6%
vs prior settlement
4.2
days to cover
≈14.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 12, 2026 Other
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors
Nov 11, 2026 Insider
Vogt Frederick G acquired via exercise 200,000 shares
Interim CEO & General Counsel @ $7.55 ($1.5M)
Nov 11, 2026 Insider
Vogt Frederick G surrendered for taxes 191,303 shares
Interim CEO & General Counsel @ $8.09 ($1.5M)
Nov 10, 2026 SEC
State Street Corp disclosed a 4.8% passive stake in Iovance Biotherapeutics as of September 30, 2026, via a Schedule…
SC 13G · Impact 3/10
Nov 10, 2026 Insider
Kirby Daniel Gordon acquired via exercise 10,000 shares
Chief Commercial Officer
Nov 5, 2026 SEC
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which includes a raised full-year 2026…
8-K · Impact 4/10
Nov 5, 2026 SEC
Iovance Biotherapeutics reported record Q3 2026 revenue of ~$122M, up ~80% YoY, with gross margin improving to ~60%…
8-K · Impact 6/10
Oct 28, 2026 Press
Iovance Biotherapeutics announced positive results from the IOV-LUN-202 Phase 2 registrational cohort of lifileucel…
Impact 7/10
Reddit
Crowd this week 50° Neutral 0 bullish · 0 bearish
Mentions, 7 days 1 1 in posts · 0 in comments
Recent posts
All social signals and their track records

SecBot reports

16 filings · 5 press releases · 5 bullish · 1 bearish · 10 neutral
All IOVA filing & press-release reports (21)